Physician profile
Natalya Chalik
NPI 1780745299
$5,940.36
in general payments reported to CMS, 2019-2025
31 companies · $607 in 2025
The $607 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $1,007 · 2021: $1,006 · 2022: $1,015 · 2023: $760 · 2024: $653 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,115.15 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $458.92 | 2019-2024 | Viberzi, Linzess |
| Amgen INC. | $411.02 | 2019-2022 | |
| Novo Nordisk INC | $396.95 | 2019-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.30 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $363.94 | 2019-2024 | Trulicity, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $313.55 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Intra-Sana Laboratories | $173.83 | 2023-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Janssen Pharmaceuticals, INC | $170.62 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.00 | 2019-2023 | Trulance |
| Bausch Health US, LLC | $163.22 | 2022-2025 | Aplenzin, Wellbutrin |
| Amarin Pharma, INC. | $157.44 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $81.72 | 2020 | |
| Merck Sharp & Dohme LLC | $76.55 | 2019-2020 | |
| Allergan, INC. | $69.13 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $55.82 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.77 | 2021-2022 | |
| Eisai INC. | $42.23 | 2019 | |
| Optinose US, INC. | $40.48 | 2019-2025 | |
| Pfizer INC. | $30.91 | 2025 | |
| Esperion Therapeutics, INC. | $29.27 | 2020-2021 | |
| Phadia US INC. | $26.87 | 2020-2022 | |
| Horizon Therapeutics Plc | $22.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.82 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.00 | 2021 | |
| Astellas Pharma US INC | $18.15 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.32 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $15.85 | 2025 | Neffy |
| Exact Sciences Corporation | $13.94 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.61 | 2025 | Zoryve |
| Supernus Pharmaceuticals, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalya Chalik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.